Drug Profile

W 0101

Alternative Names: W-0101

Latest Information Update: 20 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Pierre Fabre
Class Antineoplastics; Drug conjugates; Immunoconjugates
Mechanism of Action Apoptosis stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II Solid tumours

Most Recent Events

05 Dec 2024 Pierre Fabre Medicament terminates a phase I/II trial in Solid tumours (Late-stage disease, Metastatic disease) in Belgium, France, Spain (IV) due to delay in participants recruitment in cohort A3 and IMP manufacturing issues (NCT03316638) (EUCT2017-001842-82)
28 Aug 2019 Pierre Fabre intends to launch W 0101 in 2028 (Pierre Fabre pipeline, August 2019)
28 Aug 2019 Pierre Fabre plans a phase IIa trial in Solid tumours in March 2020 (Pierre Fabre pipeline, August 2019)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com